Jeena Sikho's Entero pharmacy tie-up is dead. Management didn't explain why.
Two calls after promising 1 lakh pharmacy doors via Entero, the deal collapsed over costs. The bed expansion is also months behind schedule.
What's new
- The Entero distribution deal is abandoned after management cited cost-sharing disagreements.
- Operational beds stand at 2,300; the target to reach 3,000 is delayed another 3-4 months.
- FY26 PAT surged 177% to ₹222 cr on ₹801 cr revenue, with EBITDA margin at 44%.
Themes from the call
Strategy execution
The Entero collapse and bed-ramp delays show a pattern: ambitious targets followed by reversals or missed timelines with thin explanations.
Growth
IPD volumes rose 65% and OPD 69% in FY26, but Q4 dipped after Iran-US tensions delayed advance bookings for roughly 250 patients.
Unit economics
₹3-4 lakh capex per bed with sub-six-month payback and 71% ROCE anchor the long-term 3,000 cr revenue thesis, but only if beds are built and filled on schedule.
Guidance watch
- FY27 PAT guided to a minimum of ₹300 cr. No revenue guidance given.
- Multi-year targets reiterated: 4-5x PAT in 4 years, ₹3,000 cr revenue in 3-5 years, 7,000-10,000 beds in 3-5 years.
- Management said it could deploy 2,000 beds in a single year once government portals are ready, but this is a capability claim, not formal guidance.
Risk flags
- Management credibility on distribution and capacity timelines is strained after the Entero collapse and repeated bed-ramp delays.
- Government revenue fell from ₹118 cr in FY25 to ₹36 cr in FY26 due to payment delays, a cash-flow dependency that remains unresolved.
- Q4 PAT was depressed by ₹21 cr in one-time charges (labor, Ind AS leasehold, ECL, health card loyalty); the adjustment needs watching.
Key quotes
-
"We finalized the agreement with Entero last week. ... as soon as we join with Entero, that number will straightaway reach 1 lakh."
— Manish Grover, MD, Feb 2026 call -
"Actually, the tie-up with Entero happened but the business model did not start because Entero was asking us to bear certain expenses."
— Manish Grover, MD, Jun 2026 call
The brief
Jeena Sikho's June call split into two stories. One was FY26: PAT up 177% to ₹222 cr, EBITDA margin at 44%, IPD volumes up 65%. The other was execution. The Entero distribution deal, which Grover said in February would deliver 1 lakh pharmacy doors "immediately," is dead. The reason given was a cost-sharing dispute. No alternative retail strategy was laid out.
The bed ramp is also lagging. Management missed its February target to open the remaining non-operational beds and now says 3,000 will take another 3-4 months. The unit economics are real (₹3-4 lakh capex per bed, sub-six-month payback), but they depend on beds getting built on time.
Government revenue collapsed from ₹118 cr to ₹36 cr in FY26 because of payment delays. Management expects a reversal when the Ayushman Yojana portal goes live, but that is another external dependency it doesn't control. The FY27 PAT floor of ₹300 cr looks achievable on the current run-rate. The path to ₹3,000 cr revenue and 4-5x PAT growth runs through promises that have already been broken twice.
The financials are strong, but the strategy updates keep going stale.